InMode Ltd. (INMD)
| Market Cap | 900.01M |
| Revenue (ttm) | 370.50M |
| Net Income (ttm) | 93.83M |
| Shares Out | 63.36M |
| EPS (ttm) | 1.43 |
| PE Ratio | 9.93 |
| Forward PE | 9.83 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 303,306 |
| Open | 14.34 |
| Previous Close | 14.31 |
| Day's Range | 14.15 - 14.34 |
| 52-Week Range | 12.72 - 16.74 |
| Beta | 2.12 |
| Analysts | Hold |
| Price Target | 17.33 (+22.0%) |
| Earnings Date | May 6, 2026 |
About INMD
InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States, Europe, Asia, and internationally. It offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women’s health conditions and procedures. The ... [Read more]
Financial Performance
In 2025, InMode's revenue was $370.50 million, a decrease of -6.16% compared to the previous year's $394.82 million. Earnings were $93.83 million, a decrease of -48.24%.
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for INMD stock is "Hold." The 12-month stock price target is $17.33, which is an increase of 22.00% from the latest price.
News
InMode Transcript: 25th Annual Needham Virtual Healthcare Conference
Q1 growth was driven by new product launches, but gross margins declined due to higher costs and increased competition. The company is expanding its product portfolio and international presence, while ongoing clinical studies and regulatory submissions target future growth. Guidance for 2026 remains cautious.
InMode to Report First Quarter 2026 Financial Results and Hold Conference Call on May 6, 2026, Expects Q1 Revenue Between $81.5M-$81.7M, Reiterates FY 2026 Revenue Guidance Between $365M-$375M
Conference call to be held on Wednesday, May 6, 2026, at 8:30 a.m. Eastern Time YOKNEAM, Israel, April 13, 2026 /PRNewswire/ -- InMode Ltd.
InMode to Present at the 25th Annual Needham Virtual Healthcare Conference
YOKNEAM, Israel, March 24, 2026 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced that Moshe Mizrahy, Chief Executive Officer an...
InMode Transcript: Oppenheimer 36th Annual Healthcare MedTech & Services Conference
Operations face ongoing disruptions in Israel, with manufacturing at 60% capacity and logistics strained. Over $600 million has been returned via buybacks, while M&A targets focus on complementary tech and Asia. Growth is expected to resume in 2027, supported by new products and organizational restructuring.
InMode Announces New Share Repurchase Program
YOKNEAM, Israel, March 13, 2026 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced that its Board of Directors has authorized a n...
InMode Transcript: Barclays 28th Annual Global Healthcare Conference
After two years of decline, expectations are for a flat top line in 2026, with organizational restructuring and new product launches aimed at supporting recovery. Margin pressures persist due to laser commoditization, but growth in new verticals and a focus on North America are key strategies.
InMode to Present at Upcoming Investor Conferences
YOKNEAM, Israel, Feb. 26, 2026 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced the participation at the following investor con...
InMode (INMD) Stock Slips As Board Ends Review
The committee, formed by InMode's board, evaluated multiple proposals for a potential transaction with help from outside financial and legal advisers. After reviewing the final bids, it concluded that...
InMode Announces Conclusion of Independent Transaction Committee Review
YOKNEAM, Israel, Feb. 23, 2026 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) a leading global provider of innovative medical technologies ("InMode" or the "Company"), today announced that the independent...
InMode Earnings Call Transcript: Q4 2025
Q4 2025 revenue rose year-over-year, but full-year sales declined 6% amid industry softness. International sales grew, while gross margins and EPS declined due to product mix and new laser launches. 2026 is expected to be a stabilization year, with new products and strategic alternatives under review.
InMode Reports Fourth Quarter and Full Year 2025 Financial Results: Quarterly GAAP Revenue of $103.9 Million and Full Year Revenue of $370.5 Million
YOKNEAM, Israel, Feb. 10, 2026 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results f...
InMode to Participate in the 13th Annual BTIG MedTech, Digital Health, Life Sciences & Diagnostics Tools Conference
YOKNEAM, Israel, Feb. 3, 2026 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced that Yair Malca, Chief Financial Officer will ho...
InMode Responds to Transaction Rumors
YOKNEAM, Israel, Feb. 2, 2026 /PRNewswire/ -- InMode Ltd. (NASDAQ: INMD), a leading global provider of innovative medical technologies ("InMode" or the "Company"), today issued the following statement...
Steel Partners Targets InMode, Citing Stock Underperformance
Steel Partners Holdings on Wednesday publicly disclosed an unsolicited proposal to acquire a controlling stake in InMode Ltd. (NASDAQ: INMD), offering shareholders a cash premium while criticizing the...
Steel Partners Holdings L.P. Announces It Has Presented $18.00 Per Share Offer for 51% of InMode Ltd.
NEW YORK--(BUSINESS WIRE)--Steel Partners Holdings L.P. (together with its affiliates, “Steel”), which beneficially owns approximately 1.3% of the outstanding shares of InMode Ltd. (Nasdaq: INMD) (“In...
InMode to Report Fourth Quarter & Full Year 2025 Financial Results and Hold Conference Call on February 10, 2026, Expects Q4 Revenue Between $103.6M-$103.8M
Conference call to be held on Tuesday, February 10, 2026, at 8:30 a.m. Eastern Time YOKNEAM, Israel, Jan. 8, 2026 /PRNewswire/ -- InMode Ltd.
InMode Transcript: Jefferies London Healthcare Conference 2025
The company has expanded from aesthetics into wellness, with strong growth in women's health and ophthalmology products. Despite a market slowdown due to high interest rates, it maintains high margins and is investing in new laser platforms and international expansion.
InMode Earnings Call Transcript: Q3 2025
Q3 2025 revenue reached $93.2 million, with strong consumables growth and expanding international sales. Gross margins declined due to tariffs, and net income fell year-over-year. Guidance for 2025 remains unchanged, with management cautious about 2026 amid macro uncertainties.
InMode Reports Third Quarter 2025 Financial Results: Quarterly Revenue of $93.2 Million, 78% Gross Margins
YOKNEAM, Israel, Nov. 5, 2025 /PRNewswire/ -- InMode Ltd. (NASDAQ: INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results fo...
InMode Appoints Michael Dennison as President of North America
IRVINE, Calif. , Nov. 3, 2025 /PRNewswire/ -- InMode Ltd.
InMode to Participate in Upcoming Investor Conferences
YOKNEAM, Israel , Oct. 30, 2025 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced the participation in the following investor co...
InMode to Report Third Quarter 2025 Financial Results and Hold Conference Call on November 5, Expects Q3 Revenue Between $92.5M-$93.0M, Reiterates FY 2025 Guidance Between $365M-$375M
Conference call to be held on Wednesday, November 5, 2025, at 8:30 a.m. Eastern Time YOKNEAM, Israel, Oct. 9, 2025 /PRNewswire/ -- InMode Ltd.
InMode Transcript: Baird Global Healthcare Conference 2025
Aesthetic market demand remains soft but has stabilized, with financing and macro headwinds impacting sales. Product innovation and expansion into new markets, including ophthalmology and women's health, are expected to drive growth. International operations are rebounding, and 5–6% annual revenue growth is targeted.
DOMA Perpetual Sends Letter Urging Board of Directors of InMode Ltd. to Return Capital to the Shareholders
Believes the Board Should Approve and Execute a 10% Buyback in Q4 2025 and Another 10% Buyback in Q1 2026 Maintains Board Has Legal and Fiduciary Duty to Act in Best Interests of Shareholders MIAMI ,...
InMode to Present at Baird 2025 Global Healthcare Conference
YOKNEAM, Israel , Sept. 2, 2025 /PRNewswire/ -- InMode Ltd.